Eurepa V 1/0.3mg Tablet belongs to the therapeutic classification of Antidiabetic Agents. The primary composition for this medicine is Repaglinide 1 MG, Voglibose 0.3 MG.

Before taking this medication, tell your doctor or healthcare professional if you are allergic to Repaglinide and voglibose; or have other allergies. This product may contain inActive ingredients, which can cause allergic reactions or other problems. Eurepa-V 1/0.3 Tablet 10's should not be stopped even if you feel better, without consulting your doctor as sugar level keeps changing. If you stop taking Eurepa-V 1/0.3 Tablet 10's abruptly, it may increase your sugar levels which could further increase the risk of eyesight loss (retinopathy), kidney (nephropathy), and nerve damage (neuropathy). Eurepa-V 1/0.3 Tablet 10's should not be taken if you have type 1 diabetes mellitus, severe kidney, or liver disease. During pregnancy/lactation, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.